Acta Scientific Gastrointestinal Disorders (ISSN: 2582-1091)

Research Article Volume 3 Issue 1

Study the Role of Combined M2-Pyruvate Kinase, Calprotectin and Occult Blood Test as Fecal Biomarkers for Early Detection of Colorectal Cancer

Atef Abo El-Soud Ali1, Ahmed Abo Zaid Ahmed2, Mohamed Gamal El Helbawy3, Huda Saad Elmehily4* and Emad Mohamed Salem5

1Proffessor of Tropical Medicine, Menoufia University, Egypt

2Lecturer of Tropical Medicine, Menoufia University, Egypt

3Lecturer of Clinical Pathology, Menoufia University, Egypt

4Tropical Medicine Department, Menoufia University, Egypt

5Gastroenterology Department NJCH, Egypt

*Corresponding Author: Huda Saad Elmehily, Tropical Medicine Department, Menoufia University, Egypt.

Received: November 25, 2019; Published: December 09, 2019

×

Abstract

Background and Study Aim: One of the main requirements of biomarkers for detecting CRC is that it must allow detection of the disease at earlier stages. The current study is designed to investigate the role of combined M2-Pyruvate kinase, Calprotectin, and Fecal occult blood test measurements as fecal diagnostic biomarkers for early detection of colorectal cancer.

Patients and Methods: Total number of 72 subjects (48 patients and 24 healthy controls) were included in the study. Patients with cancer colon and patients with organic non-malignant colorectal lesions were recruited from Oncology and Gastroenterology Outpatient Clinics and Inpatient Department Menoufia University Hospital.

Results: There was a highly significant difference between studied groups regarding age and gender (P> 0.001), cancer colon was higher among old age (mean ± SD is 58.96 ± 6.3) and males (70.8%), There was a highly significant difference between studied groups regarding Hb, CRP and ESR (P >0.001); lowest Hb level was detected in cancer group (8.7 ± 1.7). On the other hands highest CRP and ESR levels were in cancer group (7.29 ± 4.47) and (14.71 ± 6.19) respectively. There was a significant difference between studied groups regarding platelets (P >0.05); lowest platelet number was detected in cancer group (272.4 ± 66.9). There was non-significant difference between studied groups regarding WBCs (P <0.05); highest WBCs number was detected in cancer group (8.05 ± 2.3), There was a highly significant difference between studied groups regarding colonoscopy (P >0.001), There was a highly significant difference between studied groups regarding M2-Pyruvate kinase and Occult Blood (P >0.001), There was highly significant difference between M2-PK in cancer and control groups (p >0.001), There was significant difference between calprotectin in cancer and control groups (p >0.05), There was highly significant difference between occult blood in cancer and control groups (p >0.001), There was highly significant difference between Combined M2-PK and Calprotectin in cancer and control groups (p >0.001), There was highly significant difference between Combined M2-PK and Occult blood in cancer and control groups (p>0.001), There was highly significant difference between Combined M2-PK, Calprotectin and occult blood in cancer and control groups (p >0.001).

Conclusion: Our study confirms that, Colorectal Cancer (CRC) increases with age and it is more common in male, CRP and ESR increase in CRC patients, Fecal M2PK, FC and FOBT in stool increase significantly in CRC patients, Sensitivity, specificity and accuracy of screening for CRC are highest in combination of fecal M2PK, occult blood in stool and FC tests.

Keywords: Colorectal Cancer; M2-Pyruvate Kinase; Calprotectin

×

References

  1. Mary C White., et al. “Age and cancer risk: a potentially modifiable relationship”. American Journal of Preventive Medicine 46 (2014): S7-15.
  2. Morikawa T., et al. “A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population”. Gastroenterology 129 (2015): 422-428.
  3. Jessica Watson., et al. “Predictive value of inflammatory markers for cancer diagnosis in primary care: a prospective cohort study using electronic health records”. British Journal of Cancer 120 (2019): 1045-1051.
  4. Winawer SJ., et al. “Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup”. The New England Journal of Medicine 329 (1993): 1977-1981.
  5. Connie L Arnold., et al. “Third Annual Fecal Occult Blood Testing in Community Health Clinics”. American Journal of Health Behavior 3 (2016): 302-309.
  6. Jesús-Miguel Herrero., et al. “Symptom or faecal immunochemical test based referral criteria for colorectal cancer detection in symptomatic patients: a diagnostic tests study”. BMC Gastroenterology 18 (2018): 155.
  7. Virender K Sharma., et al. “Survey of the Opinions, Knowledge, and Practices of Gastroenterologists Regarding Colorectal Cancer Screening and Use of the Fecal Occult Blood Test”. The American Journal of Gastroenterology 95 (2000).
  8. JOHANN KARL., et al. “Improved Diagnosis of Colorectal Cancer Using a Combination of Fecal Occult Blood and Novel Fecal Protein Markers”. Clinical Gastroenterology and Hepatology 6 (2008): 1122-1128.
  9. Hisham K Dabbous., et al. “Evaluation of Fecal M2PK as a Diagnostic Marker in Colorectal Cancer”. Journal of Gastrointestinal Cancer 50 (2019): 442-450.
  10. Kyung-Jae Lee., et al. “Colorectal cancer screening using fecal occult blood test and subsequent risk of colorectal cancer: A prospective cohort study in Japan”. Cancer Detection and Prevention 31 (2007) 3-11
  11. Mariann Rutka., et al. “Diagnostic Accuracy of Five Different Fecal Markers for the Detection of Precancerous and Cancerous Lesions of the Colorectum” (2016).
×

Citation

Citation: Huda Saad Elmehily., et al. "Study the Role of Combined M2-Pyruvate Kinase, Calprotectin and Occult Blood Test as Fecal Biomarkers for Early Detection of Colorectal Cancer".Acta Scientific Gastrointestinal Disorders 4.1 (2020): 18-27.



News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for March Issue
    The last date for submission of articles for regular Issues is February 29, 2020.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US